Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Simplified frailty score for patients with multiple myeloma undergoing autologous stem cell transplant

Blood (2025) 146 (Supplement 1): 3987.

https://doi.org/10.1182/blood-2025-3987

Published: 2025

Journal Articles

Peripheral blood stem cell collection for patients with multiple myeloma undergoing autologous transplant after quadruplet induction

Blood (2025) 146 (Supplement 1): 7557.

https://doi.org/10.1182/blood-2025-7557

Published: 2025

Journal Articles

Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2025-4575

Published: 2025

Journal Articles

A comparison between subcutaneous isa-vrd from the isasocut study and intravenous isa-vrd from the imroz study in patients with transplant- ineligible newly diagnosed multiple myeloma

Arthur Bobin, Mohamad Mohty, Philippe Moreau, Hartmut Goldschmidt, Meletios Dimopoulos, Robert Orlowski, Cyrille Touzeau, Aurore Perrot, Thomas Chalopin, Mamoun Dib, Lydia Montes, Umer Khan, Mony Morisse, Rick Zhang, Corina Oprea, Florence Suzan Teisserenc, Thierry Facon, Xavier Leleu

Blood (2025) 146 (Supplement 1): 7566.

https://doi.org/10.1182/blood-2025-7566

Published: 2025

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique Ocio, Aurore Perrot, Jesus San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Sara Bringhen, Paula Rodriguez-Otero, Mohamad Mohty, Robert Orlowski, Meletios Dimopoulos, Xavier Leleu, María-Victoria Mateos, Philippe Moreau, Sandrine Macé, Ecrem Kodas, Christine Tekle, Umer Khan, Corina Oprea, Thierry Facon

Blood (2025) 146 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2025-2267

Published: 2025

Journal Articles

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

Blood (2025) 146 (Supplement 1): 5850.

https://doi.org/10.1182/blood-2025-5850

Published: 2025

Journal Articles

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

Blood (2025) 146 (Supplement 1): 5834.

https://doi.org/10.1182/blood-2025-5834

Published: 2025

Journal Articles

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

Sikander Ailawadhi, Divaya Bhutani, Antje Hoering, Adam Rosenthal, J Christine Ye, Prashant Kapoor, Saad Usmani, Manisha Bhutani, S. Vincent Rajkumar, Paul Gater, Robert Orlowski

Blood (2025) 146 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2025-1840

Published: 2025

Journal Articles

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia

Anath Lionel, Lorenzo Gensini, Sherif Seif, Wenli Dong, Lei Feng, Janelle Sanchez, Hima Bansal, Melody Becnel, Mahmoud Gaballa, Hans Lee, Oren Pasvolsky, Krina Patel, Jing Christine Ye, Keyur Patel, Donna Weber, Robert Orlowski, Sheeba Thomas

Blood (2025) 146 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2025-1829

Published: 2025

Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Blood (2025) 146 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2025-1033

Published: 2025

Journal Articles

Daratumumab, bortezomib, lenalidomide and dexamethasone, upfront autologous transplant and lenalidomide maintenance for newly diagnosed multiple myeloma

Blood (2025) 146 (Supplement 1): 7509.

https://doi.org/10.1182/blood-2025-7509

Published: 2025

Journal Articles

Hyperuricemia modifies multiple myeloma pathobiology and modulates conventional, novel, and immuno-oncology drug sensitivity

Upasana Ray, Isere Kuiatse, Robert Orlowski

Blood (2025) 146 (Supplement 1): 5734.

https://doi.org/10.1182/blood-2025-5734

Published: 2025

Journal Articles

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 5763.

https://doi.org/10.1182/blood-2025-5763

Published: 2025

Journal Articles

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 7454.

https://doi.org/10.1182/blood-2025-7454

Published: 2025

Journal Articles

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Blood (2025) 146 (Supplement 1): 697.

https://doi.org/10.1182/blood-2025-697

Published: 2025

Journal Articles

First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma, and solid tumor models

Jun Wei, Richard Jones, Isere Kuiatse, Hua Wang, Robert Orlowski

Blood (2025) 146 (Supplement 1): 388.

https://doi.org/10.1182/blood-2025-388

Published: 2025

Journal Articles

Single-cell transcriptomic and clonotypic characterization of Waldenström macroglobulinemia reveals intra-patient monoclonal diversity with distinct differentiation states

Minghao Dang, Sherif Seif, Maria Acevedo-Calado, Linghua Wang, Janelle Sanchez, Lorenzo Gensini, Hima Bansal, Melody Becnel, Mahmoud Gaballa, Hans Lee, Oren Pasvolsky, Krina Patel, Donna Weber, Jing Christine Ye, Robert Orlowski, Sheeba Thomas

Blood (2025) 146 (Supplement 1): 460.

https://doi.org/10.1182/blood-2025-460

Published: 2025

Journal Articles

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2025-4012

Published: 2025

Journal Articles

Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT) Following Pembrolizumab Therapy

Philippe Armand, John Kuruvilla, Alex F. Herrera, Vincent Ribrag, Pauline Brice, Catherine Thieblemont, Bastian Von Tresckow, Eunhee Kim, Robert Orlowski, Samhita Chakraborty, Patricia Marinello, Pier Luigi Luigi Zinzani

Blood (2021) 138 (Supplement 1): 3924.

https://doi.org/10.1182/blood-2021-148528

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Simplified frailty score for patients with multiple myeloma undergoing autologous stem cell transplant

Peripheral blood stem cell collection for patients with multiple myeloma undergoing autologous transplant after quadruplet induction

Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma

A comparison between subcutaneous isa-vrd from the isasocut study and intravenous isa-vrd from the imroz study in patients with transplant- ineligible newly diagnosed multiple myeloma

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia

Daratumumab, bortezomib, lenalidomide and dexamethasone, upfront autologous transplant and lenalidomide maintenance for newly diagnosed multiple myeloma

Hyperuricemia modifies multiple myeloma pathobiology and modulates conventional, novel, and immuno-oncology drug sensitivity

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma, and solid tumor models

Single-cell transcriptomic and clonotypic characterization of Waldenström macroglobulinemia reveals intra-patient monoclonal diversity with distinct differentiation states

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT) Following Pembrolizumab Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only